argenx Is Knocking on Its 52-Week High With a Pipeline Full of Rockets

Signal: BUY | Score: 65.42/100

argenx just crossed into profitability for the first time, earnings are accelerating at triple-digit rates, and the stock is sitting a breath away from all-time highs. With Q2 earnings dropping in 23 days and a myositis readout coming in Q3, the catalyst runway here is long and loaded.

The Setup

ARGX is trading at $924.76, basically kissing its 52-week high of $934.62. That is not a warning sign - that is a breakout in progress. RSI sits at 63, which is strong momentum without being overbought. The momentum score of 79 out of 100 is the standout number in this model, and it is telling you something the chart confirms: buyers are in control. The stock has nearly doubled off its 52-week low of $536, and it has done it on the back of real fundamental progress, not hype.

The Catalyst

The story here is VYVGART, and the story keeps getting bigger. Q1 2026 delivered $1.3 billion in product sales, up 63% year over year, with profits doubling to $366 million. argenx is now a profitable biotech with $4.9 billion in cash, which changes the risk profile entirely.

The FDA already made its decision on seronegative gMG back in May - a label expansion that makes VYVGART the first therapy across all gMG subtypes. Now the company is pushing into ocular MG with positive ADAPT OCULUS data already in hand and a planned sBLA submission on the way. The real near-term fireworks? Myositis topline results from the ALKIVIA study, expected in Q3 2026. H.C. Wainwright reiterated their Buy on June 25 with a $940 target, citing that exact catalyst. Q2 earnings on July 23 are another clean swing opportunity.

Bull Case

Analyst consensus target is $1,045, implying 13% upside from here. That is before a successful myositis readout, which could unlock a massive new indication.
Forward P/E of 25 is genuinely reasonable for a company growing earnings at 116% year over year. This is not a speculation trade, it is a growth-at-a-reasonable-price setup.
The seronegative gMG approval already happened. The pipeline is executing, not promising.

Bear Case

A price-to-book of 195 makes this stock very sensitive to any clinical disappointment. A failed myositis readout would hurt badly.
The beta is essentially zero (-0.033), meaning this stock moves on its own news. Any Q2 earnings miss could stall the breakout attempt right at the highs.

The Trade

Entry: $924 - $927
Target: $1,045 (analyst consensus)
Stop Loss: $870 (below recent consolidation support)
Risk/Reward: Approximately 2.3:1
Timeframe: 60 to 90 days, into the Q3 myositis readout

*This is one person's analysis, not financial advice. Always do your own research.*